在SCLC的第一线化疗-免疫疗法:双国实体研究的结果
Laura Moliner1, Núria Zellweger2, Sabine Schmid3
1Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, United Kingdom.
JTO clinical and research reports
|January 13, 2025
概括
化疗免疫疗法对扩散阶段小细胞肺癌 (ES-SCLC) 有效,即使在被排除在临床试验之外的患者中也是如此. 现实世界的数据显示了与关键试验相比的生存结果,支持其在临床实践中的使用.
科学领域:
- 在瘤学瘤学.
- 临床试验 临床试验
- 免疫治疗是一种免疫疗法.
背景情况:
- 扩散阶段小细胞肺癌 (ES-SCLC) 具有侵略性,治疗选择有限.
- 化学免疫疗法是ES-SCLC的新标准治疗方法.
- 对于从临床试验中排除的患者子组,需要真实世界的数据.
研究的目的:
- 评估ES-SCLC患者化学免疫疗法的实际有效性.
- 评估不符合关键试验条件的患者子群体的结果.
主要方法:
- 追溯双国多中心研究.
- 包括436名ES-SCLC患者,他们接受了乙胺和免疫治疗.
- 分析了整体存活率 (OS),无进展存活率,反应率和安全性.
主要成果:
- 32.6%的患者没有资格参加关键试验.
- 平均生存期为9.3个月,2年生存期为14%.
- 结果与注册试验相似,安全性概况相似.
结论:
- 这是ES-SCLC化疗免疫疗法的最大的现实世界队列.
- 生存和安全数据支持化疗免疫疗法作为一线治疗.
- 化学免疫疗法在ES-SCLC的常规临床实践中是有效的.
更多相关视频
10:29Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
Published on: August 14, 2019
10.5K
07:42Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
Published on: February 7, 2021
4.8K
相关概念视频
Targeted Cancer Therapies
7.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.0K
Treatment Resistant Cancers
2.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K
